UCLA SPORE in Prostate Cancer

UCLA SPORE 在前列腺癌中的应用

• 批准号: 7679554
• 负责人: ROBERT E REITER
• 金额: $ 234.82万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7679554
• 关键词: UCLA; SPORE; Prostate; Cancer

DESCRIPTION (provided by applicant): The UCLA Prostate Cancer SPORE program is a multidisciplinary and translational research program whose purpose is to understand the biology of prostate cancer and to develop more effective methods for prevention, diagnosis and treatment. This mission will be accomplished through (1) five major research projects focused on the application of basic and population science to the prevention, diagnosis and treatment of prostate cancer, and (2) the recruitment and development of new prostate cancer researchers and research projects through career development and developmental research projects. The UCLA prostate SPORE leverages the exciting resources and programs at UCLA, its sister institutions, as well as Cedars Sinai and City of Hope Cancer Center, to improve the care of men with prostate cancer. It collaborates extensively with other SPORE institutions and the SPORE program at the NCI to advance local and national initiatives. Over the first four years of funding, the UCLA SPORE has made significant strides, such as the development and translation of PSCA antibody therapy to the clinic, the demonstration at the molecular level that mTOR antagonism down-regulates the PIS kinase-PTEN-Akt pathway in men with PTEN null tumors, and the initiation of a novel dietary prevention trial in men undergoing prostate surgery. In this application, the five major projects are as follows: 1) Project 1: Bioengineered Antibodies Against Prostate Stem Cell Antigen (PSCA) for Prostate Cancer Imaging (Project Leaders: Anna Wu, M.D. and Robert Reiter, M.D; Project co-Leader, Robert Figlin, M.D.); 2) Project 2: Exploiting PIS Pathway Inhibitor Therapy in Prostate Cancer (Project Leaders: Hong Wu, M.D, Ph.D. and Charles Sawyers, M.D; Project co-Leaders, Robert Reiter, M..D. and Howard Scher, M.D; 3) Project 3: Lymphangiogenesis and Metastasis in Prostate Cancer (Project Leader: Lily Wu, M.D., Ph.D; Project co-Leader: David Agus, M.D.); 4) Project 4: Evaluating the role of IGFBP-3 therapy in men with prostate cancer (Project Leader: Pinchas Cohen, M.D.; Project co- Leaders: Alan Pantuck, M.D and Kuk-Wha Lee, M.D., Ph.D; 5) Project 5: Dietary Fat Modulation and targeted Therapies for Prostate Cancer Prevention (Project Leader: William Aronson, M.D.; Project co- Leaders: Pinchas Cohen, M.D. and Harvey Herschman, Ph.D.)

描述（由申请人提供）：加州大学洛杉矶分校前列腺癌孢子计划是一个多学科和转化研究计划，其目的是了解前列腺癌的生物学，并开发更有效的预防，诊断和治疗方法。这一使命将通过（1）五个主要研究项目来实现，重点是将基础和人口科学应用于前列腺癌的预防、诊断和治疗，以及（2）通过职业发展和发展研究项目招募和发展新的前列腺癌研究人员和研究项目。UCLA前列腺SPORE利用UCLA及其姊妹机构以及Cedars Sinai和City of Hope癌症中心的令人兴奋的资源和计划，以改善前列腺癌患者的护理。它与其他SPORE机构和NCI的SPORE计划广泛合作，以推进地方和国家的举措。在最初的四年资助中，UCLA SPORE取得了重大进展，例如PSCA抗体疗法的开发和临床转化，在分子水平上证明mTOR拮抗作用下调了PTEN无效肿瘤男性的PIS激酶-PTEN-Akt通路，以及在接受前列腺手术的男性中启动了一项新的饮食预防试验。在本次申报中，五大项目如下：1）项目1：前列腺癌成像用抗前列腺干细胞抗原（PSCA）生物工程抗体（项目负责人：安娜吴，医学博士，和Robert Reiter，医学博士;项目共同负责人Robert Figlin，医学博士）; 2)项目二：PIS通路抑制剂在前列腺癌治疗中的应用（项目负责人：吴红，医学博士，哲学博士。和Charles Sawyers，M.D;项目共同负责人Robert Reiter，M. D.和霍华德Scher，M.D.; 3）项目3：前列腺癌中的淋巴管生成和转移（项目负责人：Lily Wu，M.D.，博士;项目共同负责人：大卫阿古斯，医学博士）; 4)项目4：评估IGFBP-3治疗在前列腺癌患者中的作用（项目负责人：Pinchas Cohen，M.D.;项目共同负责人：Alan Pantuck，医学博士和Kuk-Wha Lee，医学博士，项目5：饮食脂肪调节和前列腺癌预防的靶向治疗（项目负责人：William Aronson，医学博士;项目共同负责人：Pinchas Cohen，医学博士和Harvey Herschman博士）